Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysis.

Expert review of anticancer therapy - 1 Jan 2000

Luo Wei, Zhu Jing, Zhang Wenxue, Yu Airu, Zhou Wei, Xu Ke

Abstract excerpt

OBJECTIVE: To systematically analyze the efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer (NSCLC). METHODS: The candidate studies were identified in PubMed, Embase, Cochrane Library, CNKI, and Wanfang databases up to 1 June 2023. Data on efficacy, prognosis, and adverse events (AEs) were extracted and calculated by meta-analysis. RESULTS: Six eligible prospective studies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Diarrhea

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 37950424
DOI: 10.1080/14737140.2023.2282606

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysis.PMID 37950424Read ↗

Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis.Semantic proximity Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.Semantic proximity Read ↗

An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.Semantic proximity Read ↗

KRAS-targeted therapy in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

[Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice].Semantic proximity Read ↗

Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis.Semantic proximity Read ↗

Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.Semantic proximity Read ↗

Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Advances in the treatment of KRASG12C mutant non–small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.